Initial Results in a Phase 1b Trial of PB-04 in Sickle Cell Disease Demonstrate Fetal Hemoglobin Induction, Additive Activity with Hydroxyurea, and Improved Red Blood Cell Sickling Parameters
Kevin H.M. Kuo(University Health Network), Susan P. Perrine(Center for Drug Evaluation and Research), Frans A. Kuypers(Children's Hospital Central California), Aidan Faller(Phoenicia Biosciences (United States)), Sandra Larkin(University of California, San Francisco), Abdullah Kutlar(Augusta University), Hanny Al‐Samkari(Harvard University), Lanetta Bronté-Hall(Institute for Myeloma & Bone Cancer Research), Patrick C. Hines, Sylvia T. Singer(UCSF Benioff Children's Hospital), Gershwin T. Blyden, Niren Patel(Augusta University), Aliya U. Zaidi, Sujit Sheth(Columbia University Irving Medical Center)
Cited by 2
Related Papers
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
|New England Journal of Medicine|2020|320
Association of genetic variation with systolic and diastolic blood pressure among African Americans: the Candidate Gene Association Resource study
|Human Molecular Genetics|2011|175
Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study
|Blood|2018|165
VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis
|Nature Medicine|2006|162